Search

Your search keyword '"OVs derived from herpes simplex virus = oHSV"' showing total 2 results
Start Over Descriptor "OVs derived from herpes simplex virus = oHSV"
2 results on '"OVs derived from herpes simplex virus = oHSV"'

1. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

Author

William F. Goins, Aofei Li, Nduka Amankulor, Joseph C. Glorioso, Balveen Kaur, Chelsea Bolyard, Paola Grandi, E. Antonio Chiocca, Mingdi Zhang, Paola Sette, Marco Marzulli, Timothy P. Cripe, Daniela Leronni, and Jianhua Yu

Subjects
0301 basic medicine, Cancer Research, OVs derived from herpes simplex virus = oHSV, Glioblastoma multiforme = GBM, Mutagenesis (molecular biology technique), extracellular matrix = ECM, Matrix metalloproteinase, MMP9, Oncolytic vectors = OVs, medicine.disease_cause, lcsh:RC254-282, Article, Virus, 03 medical and health sciences, 0302 clinical medicine, Medicine, Pharmacology (medical), Vector (molecular biology), Epidermal growth factor receptor, biology, business.industry, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, Oncolytic virus, 030104 developmental biology, Herpes simplex virus, Oncology, 030220 oncology & carcinogenesis, matrix metalloproteinase 9 = MMP9, Cancer research, biology.protein, Molecular Medicine, business
Abstract

The use of mutant strains of oncolytic herpes simplex virus (oHSV) in early-phase human clinical trials for the treatment of glioblastoma multiforme (GBM) has proven safe, but limited efficacy suggests that more potent vector designs are required for effective GBM therapy. Inadequate vector performance may derive from poor intratumoral vector replication and limited spread to uninfected cells. Vector replication may be impaired by mutagenesis strategies to achieve vector safety, and intratumoral virus spread may be hampered by vector entrapment in the tumor-specific extracellular matrix (ECM) that in GBM is composed primarily of type IV collagen. In this report, we armed our previously described epidermal growth factor receptor (EGFR)vIII-targeted, neuronal microRNA-sensitive oHSV with a matrix metalloproteinase (MMP9) to improve intratumoral vector distribution. We show that vector-expressed MMP9 enhanced therapeutic efficacy and long-term animal survival in a GBM xenograft model. Keywords: matrix metalloproteinase 9 = MMP9, extracellular matrix = ECM, Oncolytic vectors = OVs, Glioblastoma multiforme = GBM, OVs derived from herpes simplex virus = oHSV

Published
2019

2. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival.

Author

Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, and Grandi P

Abstract

The use of mutant strains of oncolytic herpes simplex virus (oHSV) in early-phase human clinical trials for the treatment of glioblastoma multiforme (GBM) has proven safe, but limited efficacy suggests that more potent vector designs are required for effective GBM therapy. Inadequate vector performance may derive from poor intratumoral vector replication and limited spread to uninfected cells. Vector replication may be impaired by mutagenesis strategies to achieve vector safety, and intratumoral virus spread may be hampered by vector entrapment in the tumor-specific extracellular matrix (ECM) that in GBM is composed primarily of type IV collagen. In this report, we armed our previously described epidermal growth factor receptor (EGFR)vIII-targeted, neuronal microRNA-sensitive oHSV with a matrix metalloproteinase (MMP9) to improve intratumoral vector distribution. We show that vector-expressed MMP9 enhanced therapeutic efficacy and long-term animal survival in a GBM xenograft model., (© 2019 The Authors.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results